Full Press Release Details
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results.
ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Key Takeaway: Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Price reaction · baseline $27.61 (2026-05-06 close) · hit after-hours · 1 other ZYME headline(s) in the window, move may be shared
day 0 close · peak
-3.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers